Plasma natriuretic peptides during supraventricular tachycardia: A study in patients with atrioventricular nodal reentry tachycardia

Abstract Full-Text HTML Download Download as PDF (Size:165KB) PP. 471-475
DOI: 10.4236/wjcd.2013.37074    2,906 Downloads   4,486 Views  


Aims: To characterize the plasma levels of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients with atrioventricular nodal reentry tachycardia (AVNRT), we measured the plasma levels of these peptides before and during tachycardia. Methods: We included 10 consecutive patients scheduled for ablation of typical AVNRT without structural heart disease. Catheters were inserted in the femoral artery, femoral vein, and coronary sinus (CS) prior to the ablation procedure. Blood samples were drawn before and after 3 min of tachycardia to measure plasma levels of ANP and BNP. Right atrial pressure (RAP) was measured at baseline. Results: Of the 10 patients, in three patients it was not possible to induce tachycardia leaving a total of 7 patients available for analysis. Mean age of the seven included patients was 40 ± 12 years (mean ± SD), five were female. ANP levels increased significantly during tachycardia in the artery (p = 0.0009) and vein (p = 0.003), but only borderline in CS (p = 0.09). BNP levels did not change during tachycardia in any location. Conclusion: ANP levels measured in the peripheral circulation increased acutely during tachycardia due to AVNRT. BNP levels did not increase.

Cite this paper

Pecini, R. , Pehrson, S. , Chen, X. , Thøgersen, A. , Kjær, A. and Svendsen, J. (2013) Plasma natriuretic peptides during supraventricular tachycardia: A study in patients with atrioventricular nodal reentry tachycardia. World Journal of Cardiovascular Diseases, 3, 471-475. doi: 10.4236/wjcd.2013.37074.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Maisel, A.S., Krishnaswamy, P., Nowak, R.M., et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine, 347, 161-167.
[2] McDonagh, T.A., Robb, S.D., Murdoch, D.R., et al. (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet, 351, 9-13.
[3] Berger, R., Huelsman, M., Strecker, K., et al. (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105, 2392-2397.
[4] Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 107, 1278-1283.
[5] de Lemos, J.A., Morrow, D.A., Bentley, J.H., et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New England Journal of Medicine, 345, 1014-1021.
[6] Schnabel, R., Lubos, E., Rupprecht, H.J., et al. (2006) B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: Results from the AtheroGene study. Journal of the American College of Cardiology, 47, 552-558.
[7] Detaint, D., Messika-Zeitoun, D., Avierinos, J.F., et al. (2005) B-type natriuretic peptide in organic mitral regurgitation: Determinants and impact on outcome. Circulation, 111, 2391-2397.
[8] Li, J. and Wang, L. (2006) B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation. Heart Vessels, 21, 137-140.
[9] Yamada, T., Murakami, Y., Okada, T., et al. (2007) Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation. Europace, 9, 770-774.
[10] Chen, L., Wei, T., Zeng, C., et al. (2005) Effect of radiofrequency catheter ablation on plasma B-type natriuretic peptide. Pacing and Clinical Electrophysiology, 28, 200-204.
[11] Cakmak, N., Sayar, N., Cakmak, M., et al. (2008) Effects of radiofrequency catheter ablation on myocardial performance index and plasma NT-Pro-BNP levels in patients with Wolff-Parkinson-White syndrome. Echocardiography, 25, 692-698.
[12] Kangawa, K. and Matsuo, H. (1984) Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochemical and Biophysical Research Communications, 118, 131-139.
[13] Ogawa, Y., Nakao, K., Mukoyama, M., et al. (1991) Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circulation Research, 69, 491-500.
[14] de Zeeuw, D., Janssen, W.M. and de Jong, P.E. (1992) Atrial natriuretic factor: Its (patho)physiological significance in humans. Kidney International, 41, 1115-1133.
[15] Yoshimura, M., Yasue, H., Okumura, K., et al. (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation, 87, 464-469.
[16] Nakagawa, O., Ogawa, Y., Itoh, H., et al. (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. Kidney International, 96, 1280-1287.
[17] Therkelsen, S.K., Groenning, B.A., Kjaer, A., et al. (2008) ANP and BNP in atrial fibrillation before and after cardioversion and their relationship to cardiac volume and function. International Journal of Cardiology, 127, 396-399.
[18] Nilsson, B., Goetze, J.P., Chen, X., et al. (2009) Increased NT-pro-B-type natriuretic peptide independently predicts outcome following catheter ablation of atrial fibrillation. Scandinavian Journal of Clinical & Laboratory Investigation, 69, 843-850.
[19] Camm, A.J., Kirchhof, P., Lip, G.Y., et al. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 12, 1360-1420.
[20] Gould, P.A., Gula, L.J., Bhayana, V., et al. (2010) Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation. Circulation: Arrhythmia and Electrophysiology, 3, 18-23.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.